Neuroendocrine carcinoma – Basic Information

Go back

Neuroendocrine carcinoma is a rare and complex cancer that develops when specialized cells throughout the body begin to grow uncontrollably, often requiring expert care and tailored treatment approaches.

Understanding Neuroendocrine Carcinoma

Neuroendocrine carcinomas represent a specific group of cancers that start in neuroendocrine cells, which are specialized cells found throughout the human body. These unique cells combine characteristics of both nerve cells, which send and receive signals from the brain, and endocrine cells, which produce hormones that control various body functions like digestion, heart rate, and sleep. When these cells become cancerous, they can develop into neuroendocrine carcinomas, which are among the more aggressive forms of neuroendocrine cancers.[1][3]

Neuroendocrine carcinomas are classified as poorly differentiated cancers, meaning the cancer cells look very abnormal under a microscope and bear little resemblance to normal neuroendocrine cells. This stands in contrast to neuroendocrine tumors, which are well-differentiated and still maintain some similarities to normal cells. The distinction between these two categories is crucial because neuroendocrine carcinomas grow much more quickly and behave more aggressively than slower-growing neuroendocrine tumors.[6][7]

These cancers most commonly occur in the digestive tract, including the stomach, intestines, and pancreas, but they can also develop in the lungs, skin, reproductive system, and various endocrine glands scattered throughout the body. Because neuroendocrine cells exist in almost every organ, neuroendocrine carcinomas can potentially arise anywhere in the body, making them particularly complex to diagnose and treat.[3][6]

Epidemiology and Occurrence

Neuroendocrine cancers, including neuroendocrine carcinomas, are considered rare conditions. Research shows that neuroendocrine tumors affect approximately six in every 100,000 people worldwide. However, the number of people being diagnosed with these cancers has been increasing over recent years, which experts believe is largely due to improved diagnostic tests that can identify these conditions more quickly and accurately than in the past.[2][12]

These cancers are extremely rare in children, teenagers, and young adults. Most people who receive a diagnosis of neuroendocrine cancer are between the ages of 50 and 60 years old. This age pattern suggests that these cancers typically develop over many years, with the body often fighting them for an extended period before symptoms become noticeable.[2][12]

The gastro-intestinal tract accounts for approximately 54% of all neuroendocrine cancer cases. Within the digestive system, these cancers are most frequently found in the large bowel and appendix, followed by the small intestine, pancreas, and stomach. Lung neuroendocrine cancers represent about 26% of cases, making them the second most common location for these tumors to develop.[8]

⚠️ Important
Over the past two decades, there has been a significant increase in diagnosed neuroendocrine cancer cases. Most of these cancers occur sporadically, meaning they are not related to another disease or inherited from family members. However, improved imaging technology and increased awareness among doctors have made it easier to detect these rare cancers earlier than in previous decades.

Causes and Development

Neuroendocrine carcinomas form when neuroendocrine cells begin to divide and multiply in an uncontrolled manner. Over time, these abnormal cells accumulate and develop into tumors that can affect the organs where the cells are located. Despite advances in medical research, scientists still do not fully understand what triggers the abnormal cell growth that leads to neuroendocrine carcinomas. The exact mechanism that causes normal neuroendocrine cells to transform into cancer cells remains an active area of investigation.[2][12]

These cells can make hormones, including important substances like adrenaline, which increases heart rate during stress, gastrin, which signals the stomach to release digestive acid and enzymes, and insulin, which the body needs to process sugars properly. When cancer develops in these cells, it can disrupt the normal production of these essential hormones, potentially causing a wide range of symptoms depending on which hormones are affected.[3]

The behavior of neuroendocrine carcinomas differs significantly from other types of cancer. While some cancers develop relatively predictably, neuroendocrine carcinomas can be particularly unpredictable in how they grow and spread throughout the body. This variability makes it challenging for doctors to predict exactly how an individual patient’s cancer will behave, which is why personalized treatment approaches are so important.[8]

Risk Factors

Researchers have identified several rare inherited syndromes that significantly increase a person’s risk of developing neuroendocrine cancers. These genetic conditions involve mutations, or changes, in certain genes that normally help control cell growth. One of the most significant risk factors is Multiple Endocrine Neoplasia, particularly Type 1, which is the most common cancer syndrome associated with neuroendocrine tumors and carcinomas. This condition causes overactive tumors to form in various organs and glands throughout the endocrine system.[2][12]

Other genetic conditions that increase risk include Von Hippel-Lindau disease and neurofibromatosis. People with these inherited conditions face a higher likelihood of developing neuroendocrine cancers during their lifetime compared to the general population. However, it’s important to note that most cases of neuroendocrine cancer occur sporadically, meaning they develop in people without any known genetic risk factors or family history of the disease.[8]

The relationship between genetics and neuroendocrine cancer is complex. Genetic mutations can be either inherited from parents or acquired during a person’s lifetime. Both inherited and acquired mutations play a significant role in how these tumors develop and behave. Understanding whether a patient has a genetic predisposition can help doctors make more informed decisions about screening, monitoring, and treatment approaches.[8]

Symptoms and Clinical Presentation

Neuroendocrine carcinomas often remain silent for extended periods, meaning they don’t cause noticeable symptoms until the tumor grows large enough to impact an organ’s function. This delayed symptom onset is one reason why these cancers can be challenging to diagnose early. When symptoms do appear, they vary considerably based on where the cancer is located in the body and whether it produces excess hormones.[2][12]

Common symptoms that patients may experience include persistent fatigue that doesn’t improve with rest, stomach pain that may be constant or come and go, chronic diarrhea, nausea and vomiting, shortness of breath that worsens over time, and coughing that sometimes produces blood. These symptoms can be confusing because they are also associated with many less serious health conditions, which sometimes leads to delays in diagnosis as doctors and patients initially explore other possible explanations.[2][12]

The symptoms depend heavily on several factors, including the precise location of the cancer, whether it produces hormones, and if it does, which specific hormone it manufactures. Some neuroendocrine carcinomas are classified as functional, meaning they release hormones that can cause hormone-related symptoms. Others are non-functional, meaning they don’t release hormones or don’t release enough to cause noticeable effects, though they can still cause symptoms by physically affecting nearby organs as they grow.[3][12]

⚠️ Important
Having these symptoms does not automatically mean you have cancer. Many common, non-serious conditions can cause similar symptoms. However, if you experience symptoms that persist or worsen over time without improvement, it’s essential to talk to a healthcare provider. Early evaluation can help identify the cause and ensure you receive appropriate care, whether for cancer or another condition.

Prevention Strategies

Currently, there are no specific, proven methods to prevent neuroendocrine carcinomas in the general population. Because researchers still don’t fully understand what causes normal neuroendocrine cells to become cancerous, developing targeted prevention strategies has proven challenging. Unlike some other cancers where lifestyle modifications can significantly reduce risk, neuroendocrine carcinomas don’t have well-established preventable risk factors that people can actively modify.[2]

However, for individuals with known genetic syndromes that increase their risk of developing these cancers, regular screening and monitoring may help detect tumors early when they are most treatable. People with conditions like Multiple Endocrine Neoplasia Type 1, Von Hippel-Lindau disease, or neurofibromatosis should work closely with their healthcare providers to establish appropriate surveillance schedules based on their specific genetic condition and family history.[2][8]

Maintaining overall good health through regular exercise, a balanced diet, avoiding tobacco products, and limiting alcohol consumption may support general cancer prevention, though these measures have not been specifically proven to prevent neuroendocrine cancers. Some evidence suggests that people with neuroendocrine conditions should particularly limit alcohol use, as the disease often affects the liver, and alcohol can place additional stress on this vital organ.[20]

Pathophysiology: How the Disease Affects the Body

The pathophysiology of neuroendocrine carcinoma involves understanding how these cancers disrupt normal body functions at the cellular and systemic levels. Neuroendocrine cells are part of the body’s complex communication system, where the brain sends nerve signals to these cells throughout the body, prompting them to make and release hormones and similar substances that keep bodily systems functioning properly. These hormones are essential for normal human development, growth, breathing, digesting food, sleeping, and responding to stressful situations.[6][7]

When cancer develops within neuroendocrine cells, it fundamentally changes how these cells grow and work. The cells begin growing out of control, no longer responding to the body’s normal signals that regulate cell division and death. As these abnormal cells accumulate, they can produce higher than normal levels of hormones, or conversely, they may lose their ability to produce hormones altogether. This disruption in hormone production can create a cascade of effects throughout the body, depending on which hormones are affected.[6]

Neuroendocrine carcinomas are classified as poorly differentiated, which means the cancer cells have changed so dramatically that they look very different from normal neuroendocrine cells when examined under a microscope. This loss of normal cell structure reflects deeper changes in how the cells function. These cancers typically grow quickly and have a higher tendency to spread to other parts of the body compared to their well-differentiated counterparts, neuroendocrine tumors.[6][9]

The mechanism by which neuroendocrine carcinomas spread involves the cancer cells breaking away from the original tumor and traveling through the bloodstream or lymphatic system to establish new tumors in distant organs. The liver is a particularly common site for these cancers to spread, though they can potentially metastasize to virtually any organ in the body. Once the cancer has spread, it becomes more challenging to treat, as doctors must address multiple tumor sites rather than a single, localized cancer.[8]

At the molecular level, neuroendocrine carcinomas may exhibit specific characteristics that distinguish them from other cancer types. They often have special secretory granules and can produce biogenic amines and polypeptide hormones. The term “neuro” in neuroendocrine refers to these dense core granules, which are similar to those found in neurons that store chemical messengers, while “endocrine” refers to the cells’ ability to synthesize and secrete hormones. Understanding these cellular characteristics helps pathologists accurately diagnose the cancer and helps oncologists select the most appropriate treatments.[9]

Ongoing Clinical Trials on Neuroendocrine carcinoma

  • Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

    Recruiting

    1 1
    Investigated drugs:
    France Germany
  • Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    1 1 1
    Denmark
  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    1 1 1
    Denmark
  • Study of daily low-dose Temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Recruiting

    1 1
    Belgium Bulgaria France Germany Italy Poland +2
  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark Finland France +8
  • Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

    Not recruiting

    1 1 1
    Investigated diseases:
    France Spain
  • Study of Cabozantinib and Avelumab for Patients with Advanced Neuroendocrine Tumors G3 Resistant to Standard Chemotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

References

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/symptoms-causes/syc-20354132

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.upmc.com/services/endocrinology/conditions/neuroendocrine-carcinomas

https://www.mdanderson.org/cancerwise/neuroendocrine-tumors–9-things-to-know.h00-159379578.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC10420169/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/what-are-nets

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/understanding-neuroendocrine-cancer/

https://neuroendocrine.org.au/what-are-nets/

https://en.wikipedia.org/wiki/Neuroendocrine_tumor

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/diagnosis-treatment/drc-20465865

https://www.mdanderson.org/cancer-types/neuroendocrine-tumors/neuroendocrine-tumor-treatment.html

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/treatment

https://winshipcancer.emory.edu/cancer-types-and-treatments/neuroendocrine-tumors/treatment.php

https://www.fredhutch.org/en/diseases/neuroendocrine-tumors/treatment.html

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/living-with-neuroendocrine-cancer/

https://netrf.org/old-for-patients/living-with-nets/symptom-management/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/living-with/coping

https://www.uchicagomedicine.org/forefront/cancer-articles/2023/september/pancreatic-nets-patient-chris-meyer

https://www.webmd.com/cancer/features/neuroendocrine-tumors-self-care

https://www.rockymountaincancercenters.com/neuroendocrine-tumors/navigating-the-patient-journey

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

What is the difference between a neuroendocrine tumor and a neuroendocrine carcinoma?

Neuroendocrine tumors are well-differentiated cancers where cells still look somewhat similar to normal neuroendocrine cells and may grow slowly to moderately. Neuroendocrine carcinomas are poorly differentiated, meaning their cells look very abnormal and grow rapidly. This distinction is critical because carcinomas are more aggressive and require different treatment approaches than tumors.

How common are neuroendocrine carcinomas?

Neuroendocrine cancers overall are rare, affecting about six in every 100,000 people worldwide. Neuroendocrine carcinomas represent a subset of these cases and are even less common. However, diagnoses have been increasing due to improved detection methods and better awareness among healthcare providers.

Where in the body do neuroendocrine carcinomas most commonly occur?

These carcinomas most commonly develop in the digestive tract, including the stomach, intestines, appendix, and pancreas, accounting for about 54% of cases. The lungs are the second most common location, representing approximately 26% of cases. However, they can potentially develop anywhere neuroendocrine cells exist, including the skin, reproductive organs, and various endocrine glands.

Are neuroendocrine carcinomas hereditary?

Most neuroendocrine carcinomas occur sporadically, meaning they are not inherited. However, certain rare genetic syndromes like Multiple Endocrine Neoplasia Type 1, Von Hippel-Lindau disease, and neurofibromatosis can significantly increase a person’s risk of developing these cancers. People with these genetic conditions should undergo regular screening and monitoring.

What age group is most affected by neuroendocrine carcinomas?

Neuroendocrine carcinomas are extremely rare in children, teenagers, and young adults. Most people diagnosed with these cancers are between the ages of 50 and 60 years old, suggesting these cancers typically develop slowly over many years before being detected.

🎯 Key takeaways

  • Neuroendocrine carcinomas are poorly differentiated, fast-growing cancers that look very different from normal cells under a microscope, making them more aggressive than neuroendocrine tumors.
  • These rare cancers affect approximately six in 100,000 people worldwide, with diagnoses increasing due to better detection technology rather than a true rise in disease occurrence.
  • Most neuroendocrine carcinomas develop in the digestive system or lungs, but can appear anywhere in the body where neuroendocrine cells exist.
  • Symptoms often don’t appear until the tumor affects organ function, which can delay diagnosis and make early detection challenging.
  • While most cases occur sporadically, certain inherited genetic syndromes significantly increase cancer risk and warrant regular monitoring.
  • Scientists still don’t fully understand what triggers normal neuroendocrine cells to become cancerous, making prevention strategies difficult to develop.
  • The unique zebra stripe symbol used by neuroendocrine cancer organizations reflects how each patient’s cancer behaves differently, requiring personalized treatment approaches.
  • People diagnosed between ages 50 and 60 represent the majority of cases, suggesting these cancers develop over many years before detection.